Clinical trials
ATTR Amyloidosis clinical trials
Below are recruiting attr amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06465810Recruiting
Observational study for ATTR amyloidosis patients
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
La Jolla, CaliforniaAges 18–130 - NCT06355934Recruiting
Observational study of ATTR amyloidosis treatment patterns
This study looks at the health records of people with ATTR amyloidosis to understand how the disease is treated and what happens over time. It helps doctors learn more about this condition so they can improve care.
Eden Prairie, MinnesotaAges Any age - NCT04561518Recruiting
Study of people with TTR amyloidosis worldwide
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
La Jolla, CaliforniaAges Any age - NCT06034405Recruiting
Checking spine tissue for heart amyloidosis signs
This trial is looking at leftover tissue from past spine surgeries to see if it contains signs of a heart condition called TTR amyloidosis. It may help find people who have this condition early.
Beverly Hills, CaliforniaAges 50 years+ - NCT06251778Recruiting
National study of ATTR heart amyloid patients on tafamidis
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
PaviaAges 18–99 - NCT06458374Recruiting
Heart Amyloidosis in Carpal Tunnel Surgery Patients
This study looks for people who had carpal tunnel surgery at Ålesund Hospital to check for a rare heart condition called ATTR amyloidosis. It aims to find the disease early and see how common it is.
Ålesund, Møre og RomsdalAges 50 years+ - NCT06836011Recruiting
Heart valve leakage study in a type of amyloid heart disease
This study looks at how common and how serious heart valve leaks are in people with transthyretin amyloid cardiomyopathy (a condition where abnormal protein builds up in the heart). The goal is to better understand these leaks and how they affect long-term health.
Graz, StyriaAges 18 years+ - NCT06539208RecruitingPhase 1/Phase 2
Study of YOLT-201 for transthyretin amyloidosis with nerve or heart damage
This trial tests an experimental gene-editing medicine called YOLT-201 for people with a type of amyloidosis that damages nerves or the heart. It aims to see if one or two doses can safely stop the disease from getting worse.
Beijing, Beijing MunicipalityAges 18–80 - NCT07689331Recruiting
Hungarian national amyloidosis study
This study creates a registry for people diagnosed with systemic amyloidosis in Hungary. It helps doctors better understand the condition by collecting medical history and tracking outcomes over time.
BalatonfüredAges 18 years+ - NCT07314268Recruiting
Study of tiny blood particles in heart amyloidosis
This study looks at tiny particles called extracellular vesicles in the blood of people with a specific type of heart amyloidosis. It aims to find better ways to track the disease and predict outcomes.
São Paulo, São PauloAges 18 years+ - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Tucson, ArizonaAges 18–90 - NCT07398950Enrolling by invitation
AI screening for a heart condition called ATTR-CM
This study uses artificial intelligence (AI) to look at your heart tests (ECG and echo) and find people who might have a specific heart muscle disease called ATTR-CM. The goal is to catch it earlier so treatment can start sooner.
New Haven, ConnecticutAges 18 years+ - NCT07695701RecruitingPhase 4
Heart imaging study for a new ATTR-CM treatment
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
St Louis, MissouriAges 18–80 - NCT04535349Recruiting
Imaging heart uptake of bone tracer in ATTR amyloidosis
This study uses special imaging tracers to see how much they build up in the heart in people with cardiac transthyretin (ATTR) amyloidosis. It may help researchers better measure disease activity and understand who benefits from treatments like tafamidis.
CaenAges 18–100 - NCT07124377Recruiting
Study of hereditary ATTR amyloidosis symptoms
This study looks at how a specific genetic change (Val50Met) affects people with hereditary ATTR amyloidosis. It may help doctors better understand the condition and its symptoms.
Charata, Chaco ProvinceAges 20 years+ - NCT07033715Recruiting
Exercise for hereditary ATTR amyloidosis in Portugal
This trial tests whether a structured exercise program can help people with hereditary ATTR amyloidosis (a condition that affects nerves and organs). It is for people in Portugal with early to moderate disease who can safely exercise.
Maia, Porto DistrictAges 18 years+ - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Phoenix, ArizonaAges 18 years+ - NCT05444920Recruiting
Web network for people with amyloidosis in Italy
This trial builds an Italian online network to learn from people who may have amyloidosis (an abnormal protein condition). It collects information from participating centers and could help doctors better understand different types of amyloidosis.
Legnano, MIAges 18–99 - NCT04935021RecruitingPhase 4
Study of ATTR cardiac amyloidosis in patients and gene carriers
This study looks at ATTR cardiac amyloidosis (a condition caused by an inherited protein change) in people who have the disease or carry the gene. It may help researchers learn how ATTR affects the heart and how care can be improved.
Hangzhou, ZhejiangAges 18–80 - NCT05951816RecruitingPhase 1
Imaging study for amyloidosis in heart and body
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Knoxville, TennesseeAges 18 years+ - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
Phoenix, ArizonaAges 18 years+ - NCT06907836Recruiting
Transthyretin cardiac amyloidosis in internal medicine
This study looks back at medical records of patients who were diagnosed with transthyretin cardiac amyloidosis (a type of protein buildup in the heart) while hospitalized in internal medicine at Strasbourg University Hospitals between 2013 and 2023. It aims to describe their health journey and outcomes.
StrasbourgAges 18 years+ - NCT06291805Recruiting
Understanding wtATTR-CM heart disease (TRACE 1)
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
Aarhus, Arrhus NAges 18 years+ - NCT05489549Recruiting
Study of heart amyloid risk in people with TTR gene variants
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
New York, New YorkAges 30–80
Hear when a new ATTR Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for attr amyloidosis?
- Yes. Clin2 currently lists 35 recruiting attr amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a attr amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a attr amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.